Oncology Stakeholders Summit, Spring 2015

Tap into peer-to-peer dialogues covering different therapeutic areas in easy to digest videos, featuring managed care thought leaders.

Closing Remarks and Final Considerations
July 14, 2015 – 
During the final segment of this program, part of the Oncology Stakeholders Summit, Spring 2015 series, Bruce Feinberg, DO, asks Scott Gottlieb, MD; Brian Kiss, MD; Michael Kolodziej, MD; and Ted Okon, MBA, to further consider how the issues discussed during this program could be addressed.
Concerns Surrounding Enrollment into the Oncology Care Model
July 14, 2015 – 
Brian Kiss, MD; Michael Kolodziej, MD; and Ted Okon, MBA, discuss why payers may be hesitant to apply for enrollment into CMS's Oncology Care Model.
The Oncology Care Model: Additional Concerns
July 14, 2015 – 
During this segment, the managed care stakeholders continue to discuss the potential impact of CMS's Oncology Care Model on physicians and their practices.
Analysis of the Oncology Care Model
July 07, 2015 – 
Bruce Feinberg, DO; Scott Gottlieb, MD; and Ted Okon, MBA, discuss the recent establishment of the Oncology Care Model by the CMS and compare its structure with the Community Oncology Alliance's Oncology Medical Home model.
Drug Spend, Pricing, and Development
July 07, 2015 – 
During this segment, the managed care stakeholders discuss drug spending in oncology and its relation to the overall cost of cancer care. Additionally, they consider which stakeholders should work with pharmaceutical companies during the early stages of drug development, and to what degree stakeholders should collaborate with pharma.
Government Intervention in Drug Pricing
July 06, 2015 – 
Scott Gottlieb, MD, and Ted Okon, MBA, discuss controversies surrounding a proposed legislative amendment that would allow the government to negotiate drug pricing with pharmaceutical companies.
Additional Pricing Considerations
July 06, 2015 – 
During this segment, the managed care stakeholders consider additional factors that influence prices for oncology drugs as well as for medications for other disease states.
Factors That Influence Drug Pricing
June 25, 2015 – 
Bruce Feinberg, DO, and Scott Gottlieb, MD, discuss how various factors influence the price of new drugs and describe potential policy solutions to address concerns regarding drug pricing.
Additional Reimbursement Considerations in Oncology
June 25, 2015 – 
The managed care stakeholders further explore various reimbursement models in oncology and their impact on clinical practice.
The Evolution of Buy-and-Bill
June 25, 2015 – 
Michael Kolodziej, MD, and Brian Kiss, MD, discuss the origins of the buy-and-bill model and describe changes needed in the model based on the evolution of healthcare reimbursement strategies in the United States.
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.